It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GLTO’s FA Score shows that 1 FA rating(s) are green whileLSB’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GLTO’s TA Score shows that 4 TA indicator(s) are bullish while LSB’s TA Score has 3 bullish TA indicator(s).
GLTO (@Biotechnology) experienced а -0.02% price change this week, while LSB (@Biotechnology) price change was -11.59% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.
GLTO is expected to report earnings on Nov 05, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
GLTO | LSB | GLTO / LSB | |
Capitalization | 6.76M | 52M | 13% |
EBITDA | -19.68M | -220.1M | 9% |
Gain YTD | 10.301 | -21.301 | -48% |
P/E Ratio | N/A | N/A | - |
Revenue | 0 | 672M | - |
Total Cash | 19.7M | 49.5M | 40% |
Total Debt | 32K | 369M | 0% |
GLTO | LSB | |
---|---|---|
RSI ODDS (%) | 11 days ago66% | 11 days ago40% |
Stochastic ODDS (%) | 11 days ago90% | 11 days ago34% |
Momentum ODDS (%) | 11 days ago78% | 11 days ago47% |
MACD ODDS (%) | 11 days ago86% | N/A |
TrendWeek ODDS (%) | 11 days ago79% | 11 days ago66% |
TrendMonth ODDS (%) | 11 days ago90% | 11 days ago44% |
Advances ODDS (%) | 17 days ago79% | 16 days ago74% |
Declines ODDS (%) | 11 days ago88% | 11 days ago85% |
BollingerBands ODDS (%) | 11 days ago90% | 11 days ago41% |
Aroon ODDS (%) | 11 days ago90% | 11 days ago90% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
NBSMX | 52.07 | 0.41 | +0.79% |
Neuberger Berman Small Cap Growth Instl | |||
TRZKX | 63.15 | 0.46 | +0.73% |
T. Rowe Price International Discovery Z | |||
JEMMX | 9.45 | 0.05 | +0.53% |
JHancock Emerging Markets Equity I | |||
MRJCX | 9.94 | 0.02 | +0.20% |
Morgan Stanley Multi-Asset Real Return C | |||
MXMTX | 10.94 | 0.02 | +0.18% |
Empower Small Cap Growth Investor |
A.I.dvisor indicates that over the last year, GLTO has been loosely correlated with ACLX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if GLTO jumps, then ACLX could also see price increases.
Ticker / NAME | Correlation To GLTO | 1D Price Change % | ||
---|---|---|---|---|
GLTO | 100% | +10.78% | ||
ACLX - GLTO | 34% Loosely correlated | -0.79% | ||
FULC - GLTO | 30% Poorly correlated | -0.50% | ||
TERN - GLTO | 30% Poorly correlated | -1.56% | ||
INMB - GLTO | 30% Poorly correlated | -4.02% | ||
AUTL - GLTO | 30% Poorly correlated | N/A | ||
More |
A.I.dvisor indicates that over the last year, LSB has been loosely correlated with STTK. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if LSB jumps, then STTK could also see price increases.
Ticker / NAME | Correlation To LSB | 1D Price Change % | ||
---|---|---|---|---|
LSB | 100% | +16.12% | ||
STTK - LSB | 38% Loosely correlated | +1.83% | ||
BCTX - LSB | 30% Poorly correlated | -1.82% | ||
GNFT - LSB | 23% Poorly correlated | +0.73% | ||
GLTO - LSB | 23% Poorly correlated | +10.78% | ||
DSGN - LSB | 21% Poorly correlated | +6.75% | ||
More |